SCHEMBL3348285

SCHEMBL3348285

Oc1nc(Nc2cccc(Cl)c2)ncc1Br

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 4/20 0.58
SYK P43405 2/20 0.57
HDAC3 O15379 1/20 0.56
HDAC1 Q13547 1/20 0.56
HDAC2 Q92769 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
CDK1 P06493 1/20 0.55
GRM5 P41594 3/20 0.53
MAOB P27338 2/20 0.53
JAK2 O60674 1/20 0.49
JAK1 P23458 1/20 0.49
JAK3 P52333 1/20 0.49
MAOA P21397 1/20 0.49
ABL1 P00519 1/20 0.49
BCR P11274 1/20 0.49
PRKCA P17252 1/20 0.49
PRKCD Q05655 1/20 0.49
CAMK2D Q13557 2/20 0.48
MAPT P10636 2/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3449361 0.85 IGF1R (0.61) IGF1RSYKHDAC3HDAC1HDAC2
SCHEMBL13898607 0.85 SYK (0.76) IGF1RSYKHDAC6CDK1CYP3A4
SCHEMBL3345413 0.83 SYK (0.57) IGF1RSYKGRM5JAK3
SCHEMBL3450173 0.83 SYK (0.57) IGF1RSYKHDAC1CDK1GRM5
SCHEMBL10998087 0.83 SYK (0.57) IGF1RSYKHDAC3HDAC1HDAC2
SCHEMBL13310459 0.82 IGF1R (0.68) IGF1RSYKHDAC6CDK1JAK2
SCHEMBL13310349 0.81 MAPK1 (0.54) SYKHDAC3HDAC1HDAC2HDAC6
SCHEMBL5036517 0.79 CDK19 (0.62) IGF1RSYK
SCHEMBL3449832 0.79 SYK (0.52) IGF1RSYKMAPTMEN1NPC1
SCHEMBL3949289 0.79 HDAC3 (0.64) IGF1RSYKHDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD IGF1R 4845/4885SYK 804/4885HDAC3 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.